Gene Editing for Human Therapies Just Got a Shortcut: What the FDA’s New Draft Guidance Means for Your Business

In plain terms, the FDA is telling companies that develop gene-editing therapies: you do not have to start from scratch every time. If you already have data from your own earlier work, from a manufacturing partner, from published research, or from a shared industry database, the FDA may let you use that data to support a new product instead of running the same tests all over again. 

The guidance is aimed at therapies for rare and life-threatening diseases, but its reach is much wider. It covers any human gene therapy product that uses genome editing in body cells, whether that product uses CRISPR, base editing, prime editing, epigenetic editing, or another method. And some of the guidance’s principles may apply to gene therapies that do not involve genome editing at all, such as those using viral vectors or nanoparticle delivery. 

The Acting Director of the FDA’s Center for Biologics Evaluation and Research (CBER), Karim Mikhail, described the guidance as part of the FDA’s effort to “get safe and effective cell and gene therapies to patients faster.” It does not lower the bar for safety or effectiveness. Instead, it gives companies a clearer path to avoid doing work that has already been done, which can mean lower costs, shorter timelines, and faster access for patients. 

The guidance is a draft. It is not final law. But it is a strong signal of how the FDA is thinking, and companies that engage now will be better positioned when the final version is issued. 

Comments are due by September 1 and may be submitted electronically through Regulations.gov.

Why This Matters to You

This guidance is not just for companies working on rare diseases. It touches anyone involved in building, funding, manufacturing, or regulating genome-editing therapies. Below is a breakdown of why different types of organizations should pay attention.

If you are a pharma or biotech company developing genome-editing therapies, this guidance could meaningfully reduce the time and money you spend getting to the clinic. The FDA is saying that if you use the same delivery system (say, a lipid nanoparticle (LNP)) across multiple products, you may be able to use safety and distribution data from one product to support another. The same goes for manufacturing processes, quality-testing methods, and stability data. If you are running multiple programs off a common platform, the savings could add up quickly. 

If you are a contract development and manufacturing organization (CDMO) or a technology platform provider, the guidance opens a new strategic role for you. The FDA now explicitly says that data held by third parties, including CDMOs and raw-material suppliers, can be submitted through master files and referenced by multiple drug sponsors. That means your manufacturing data, your quality-testing methods, and your process-validation results can become shared assets that help your clients move faster. This could be a competitive differentiator for organizations that invest in building and maintaining high-quality master files.

If you are an investor or venture capital firm funding gene-editing startups, this guidance could change how you evaluate pipeline risk. Early-stage companies that build on shared platforms now have a path to reduce the cost and time of getting from lab to clinical trial. Companies that can point to platform data, whether their own or licensed from a partner, may be able to file stronger regulatory submissions with fewer studies. That lowers the capital required to reach first-in-human studies, which matters in a sector where development costs are a major barrier.

If you are in the longevity or healthspan space, pay close attention even though this guidance does not mention aging. The FDA still does not recognize aging as a disease, so companies working on the biology of aging must anchor their programs in specific disease indications like macular degeneration, cardiovascular disease, or pulmonary fibrosis. But many longevity companies are already doing exactly what this guidance supports: running multiple disease-specific programs built on a common gene-editing platform. The ability to share data across those programs, rather than repeating the same tests for each one, could be especially valuable for capital-constrained startups in this space. 

If you are a patient advocacy organization, academic research group, or research hospital, the guidance encourages the creation of shared databases and data-sharing consortia that support development across multiple sponsors. The FDA is signaling that collaborative data efforts are welcome and can be used in regulatory submissions. If your organization generates natural-history data, real-world evidence, or other research that could support gene-editing product development, this guidance gives that work added regulatory value. 

What the Guidance Says

The core idea behind the guidance is simple: companies should be able to build on what is already known. The FDA calls this “prior knowledge” and divides it into two categories. 

The first category is public knowledge, which includes things like published scientific studies, pharmacopeial standards (official references for drug quality), and widely accepted scientific principles. This is information that is available to everyone and does not belong to any single company.

The second category is platform knowledge, which is data that comes from developing and manufacturing similar products using the same or very similar technology. A “platform” can be a manufacturing process, a delivery method like an LNP, an editing method like CRISPR-Cas9, or a combination of these. Platform knowledge can be held internally by a company, submitted to the FDA by a third party through a master file, drawn from published literature, or generated through collaborative data-sharing efforts. 

An important point: Companies do not need a formal “platform technology designation” from the FDA to use these provisions. Any company that can provide a sound scientific reason why existing data applies to its product can propose to use that data in its regulatory submission. 

The guidance covers three main areas where prior knowledge can be used. 

In the area of manufacturing and quality (called “CMC” in regulatory language), the guidance says companies may be able to share testing methods, quality specifications, stability data, process-validation results, and more across products that use the same platform. For example, if a company has already validated a manufacturing process for one gene-editing product, it may be able to use that validation to support a second product made the same way, potentially with fewer required test batches. 

In the area of nonclinical (animal and lab) studies, the guidance explains when safety data, biodistribution data (where the product goes in the body), and toxicology data from one product can support another. For example, biodistribution data for an LNP-based therapy might be reusable for a different therapy that uses the same LNP, as long as the physical properties of the LNP are similar and the different cargo is not expected to change how the LNP behaves. Similarly, certain toxicology studies, like genotoxicity tests, may be shared across LNP products where all the lipid components are identical.

In the area of clinical data, the guidance says that data from earlier clinical trials may help shape the design of new trials, including decisions about dosing, monitoring schedules, and safety definitions. It also supports leveraging natural-history studies and real-world evidence to support product development. 

What the Guidance Does Not Say

This guidance has clear limits, and it is important to understand them. 

It does not let companies skip safety testing for new gene targets. Every new guide RNA (the molecule that directs the editing tool to its target in the genome) needs its own safety evaluation for off-target effects, meaning unintended edits at the wrong place. You cannot borrow off-target safety data from a product that uses a different guide RNA. Likewise, on-target editing results (what happens at the intended site) are specific to each location in the genome and generally cannot be transferred between products.

It does not eliminate the need for product-specific data. Even when prior knowledge is used, the FDA expects companies to justify why that data is relevant to the new product. The guidance does not create a blanket pass. 

It does not create a regulatory pathway for aging as a disease. It does not validate biomarkers of biological aging as endpoints for clinical trials. Longevity companies will still need to design their programs around conventional disease indications and endpoints.

It does not address germline editing, meaning changes to DNA that could be inherited by future generations. That remains outside the scope of approved or investigational human use in the United States.

Finally, the guidance is not binding. It reflects the FDA’s current thinking and offers recommendations, but it does not create legal requirements. Companies can propose alternative approaches as long as they satisfy applicable laws and regulations. 

Where This Fits in the Bigger Picture

This guidance does not stand alone. It is part of a broader push by the FDA to speed up cell and gene therapy development while maintaining safety standards.

A companion draft guidance, also recently issued, addresses how to assess the safety of genome editing using next-generation sequencing, the technology used to detect unintended edits. Together, these two documents give companies a clearer picture of both what data they can borrow and how they should evaluate safety for each new product.

The FDA has also launched its Plausible Mechanism Framework, which is designed to accelerate individualized therapies for ultra-rare diseases. The prior-knowledge guidance provides the tools and data-sharing strategies that help companies build the evidence base that framework requires.

Additionally, the guidance was issued as part of a PDUFA VII commitment, a pledge the FDA made as part of the user-fee reauthorization process to publish guidance on leveraging prior knowledge for cell and gene therapy products. This means it has been on the FDA’s agenda for some time and reflects a considered policy direction.

What You Should Do Now

Organizations across the gene-editing ecosystem should consider several practical steps in response to this guidance.

Review your current and planned programs for shared elements. If you are running multiple gene-editing programs that use the same delivery system, editing method, or manufacturing process, map out where platform data could be reused. The cumulative savings from sharing data on manufacturing validation, analytical methods, stability, and nonclinical studies across programs could be significant. 

Talk to the FDA early. The guidance itself recommends engaging with the FDA as early as possible through INTERACT meetings (Initial Targeted Engagement for Regulatory Advice on CBER/CDER Products) or pre-IND meetings to discuss data-leveraging strategies before investing in studies that may turn out to be unnecessary. 

Explore data-sharing arrangements. If you are a CDMO, platform-technology provider, or raw-material supplier, consider establishing or updating FDA master files that your clients can reference. If you are a sponsor, ask your manufacturing and technology partners whether they have master files that could support your submissions. 

Submit comments on the draft guidance. This is a draft. The FDA is asking for input, and the comments that come in will shape the final version. If you believe the guidance should go further (for example, by more explicitly addressing multi-indication platform development, or by providing more clarity on data-sharing for non-genome-editing cell therapies), now is the time to say so. Comments may be submitted electronically at Regulations.gov; the deadline is stated in the Federal Register notice accompanying the guidance.

How We Can Help

ArentFox Schiff’s Longevity & Healthspan group combines the firm’s FDA regulatory, health care, intellectual property, corporate, privacy, and government relations capabilities to serve companies across the gene therapy and longevity value chain. For questions about this guidance or what it means for your business, contact the authors of this alert or one of the industry group leaders.